[{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"MinervaX","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GBS-NN\/NN2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Two-Component COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"XMT-1592","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"ImmuneOnco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMM47","moa":"CD24","graph1":"Oncology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Autolus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IQVIA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ Inapplicable"},{"orgOrder":0,"company":"IQVIA","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter And Eliza Hall Institute Of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research"},{"orgOrder":0,"company":"IQVIA","sponsor":"Nocion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NOC-110","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Fervent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FP-101","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OG-6219","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ ASLAN Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ ASLAN Pharmaceuticals"},{"orgOrder":0,"company":"IQVIA","sponsor":"Tikomed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"LMW-Dextran Sulfate","moa":"TGF-beta","graph1":"Neurology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inozyme Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inozyme Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MEDI-546","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Humacyte","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Genetic Disease","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"IQVIA \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ GSK"},{"orgOrder":0,"company":"IQVIA","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TAK-242","moa":"Toll-like receptor 4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Kintor Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Ixovex-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Undisclosed","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ICELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AVT05","moa":"TNF-alpha receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Arthrosi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AR882","moa":"Urate anion exchanger 1 (URAT1)","graph1":"Nephrology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI690517","moa":"ALDOS","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Spero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"ProtoKinetix","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"PKX-001","moa":"COX-2 expression","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ ProtoKinetix","highestDevelopmentStatusID":"4","companyTruncated":"IQVIA \/ ProtoKinetix"},{"orgOrder":0,"company":"IQVIA","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"4","companyTruncated":"IQVIA \/ IQVIA"}]

Find Clinical Drug Pipeline Developments & Deals by IQVIA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          January 29, 2025

                          Lead Product(s) : Obecabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : Autolus Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          August 12, 2024

                          Lead Product(s) : Ixovex-1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : PsiVac Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 16, 2024

                          Lead Product(s) : NOC-110

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Recipient : Nocion Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          January 12, 2024

                          Lead Product(s) : Efgartigimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : Argenx

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 18, 2023

                          Lead Product(s) : Nirsevimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 14, 2023

                          Lead Product(s) : IMM47

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : ImmuneOnco

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 26, 2023

                          Lead Product(s) : Efgartigimod

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Recipient : Argenx

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the collaboration, Blue Water Biotech and IQVIA will market Blue Water’s commercial portfolio including, Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for benign prostatic hyperplasia and Zontivity (vorapaxar).

                          Product Name : Entadfi

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 21, 2023

                          Lead Product(s) : Finasteride,Tadalafil

                          Therapeutic Area : Urology

                          Highest Development Status : Approved FDF

                          Recipient : Blue Water Vaccines

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 18, 2023

                          Lead Product(s) : Acellular Tissue Engineered Vessel

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Recipient : Humacyte

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 18, 2023

                          Lead Product(s) : Efgartigimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : Argenx

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank